The Paris System for Reporting Urinary Cytology (TPS) published in 2016 provides a standardized approach to evaluating urine cytology. In the authors' practice, a TPS-like approach was adopted in 2012 using similarly defined cytologic criteria and correlating cystoscopic findings, and they also began incorporating the use of cell block (CB) material. The objective of the current study was to assess whether this TPS-like approach with the use of CB, as well as direct implementation of TPS, improved the diagnostic value of urine cytology. METHODS: In total, 188 consecutive urine cytology specimens from 2010 through 2016 that had concurrent or subsequent histologic specimens available were retrospectively analyzed for diagnostic correlation. Urine cytology performance was compared between the periods 2010 to 2012 (pre-TPS-like), 2013 to 2016 (TPS-like), and after TPS reclassification, including blind review by a cytopathologist.
INTRODUCTION
Urine cytology is one of the primary diagnostic modalities used for the screening and surveillance of patients with urothelial carcinoma (UC). Despite its widespread use, urine cytology has been commonly critiqued for the lack of standardized or reproducible criteria, low sensitivity in diagnosing low-grade noninvasive lesions, and wide interobserver variability. 1, 2 In particular, the diagnosis of atypical urothelial cells (AUC) was used liberally and inconsistently and caused confusion for clinicians and patients. 1 Thus, The Paris System for Reporting Urinary Cytology (TPS), published in 2016, was proposed to create a more standardized approach for urine cytology that includes specific diagnostic categories and cytomorphologic criteria. 3 On the basis of the current understanding of the pathogenesis and biologic behavior, UC is divided into two major Cancer Cytopathology September 2018 groups: low grade and high grade. TPS recognizes that high-grade UC (HGUC), which is often muscle-invasive, poses a significantly higher risk of progression and worse overall survival, with a mortality rate of approximately 60%, compared with its low-grade (LG) counterpart. 4 LGUCs constitute approximately 70% of bladder UCs, are generally nonmuscle-invasive, have a good prognosis, and are readily detected by cystoscopy. Therefore, the guiding principle of TPS is to detect HGUC while minimizing the detections of LGUC, because cytology has poor sensitivity for detecting LGUC. 5 The other important goal of TPS is to refine the category of AUC into a reproducible and clinically meaningful category. TPS defines specific cytomorphologic criteria required for the diagnosis of AUC, suspicious for HGUC (SHGUC), and HGUC, with the goal of accurately identifying HGUC. In TPS, cytologic atypia secondary to non-neoplastic causes is included in the negative for HGUC (NHGUC) category instead of the AUC category. For example, under TPS, viropathic changes associated with Polyoma virus are not classified as AUC; whereas, before TPS, Polyoma virus was reported as atypical in many practices. 6 On the basis of this fundamental change in how AUC is reported, TPS claims that it reduces the number of AUC diagnoses while making the AUC category more specific for HGUC, without decreasing the overall sensitivity of urine cytology for the detection of HGUC.
In our own practice, we similarly recognized that, although pathologists were consistently good at diagnosing HGUC, the atypical category historically suffered because of a lack of well defined criteria, as nearly onehalf of our urine cytology diagnoses received the label atypical. Previously in our laboratory, any clusters (especially in voided samples) were called atypical, and atypical urothelial cells applied to potentially both low-grade and high-grade lesions despite their vastly different treatment and management. In 2012, we adopted a TPS-like approach and restricted our diagnosis of AUC to specimens with pure cytologic atypia. In addition, given the routine use of cell blocks (CBs) in nongynecologic cytology, 7 we also sought to improve our diagnoses further with the more routine use of CB material generated from residual urine samples. In the current study, we evaluated the performance of TPS compared with our TPS-like approach and the pre-2012 era as well as the contribution of CB material in improving urine cytology. To our knowledge, the routine use of CB material in urine cytology has not been reported in the literature.
MATERIALS AND METHODS
We identified 188 urine cytology specimens (urinary bladder and upper urinary tract washings and catheterized and voided urines) that had concurrent or subsequent surgical specimens from the pathology archives. All specimens were processed as ThinPrep samples and consisted of 1 slide each stained with Papanicolaou stain. Additional clinical information, including age, sex, indication for sampling (eg, hematuria vs surveillance for UC), prior Bacillus Calmette-Gurin treatment, and cystoscopic findings, was obtained from the electronic medical record.
Defining the Atypical Category Before TPS
During the period from 2010 to 2012 (pre-TPS-like), cytologic criteria used for the atypical category in urine cytology at our institution differed from TPS criteria, in that they were subjective and poorly defined using a variety of descriptive terminology. From 2013 to 2016 (TPS-like), the criteria for atypical became more stringent and similar to TPS criteria, with only the following differences: 1) architectural findings (eg, urine samples with large clusters of urothelial cells with overlapping nuclei, a slight increase in the nucleus-to-cytoplasm [N:C] ratio, and without other abnormal changes) qualified as atypical, 2) atypia because of stone or Bacillus Calmette-Gurin therapy was not used as an exclusion criterion, and 3) the cytologic findings were not correlated with clinical or cystoscopic findings. Criteria for the SHGUC and HGUC categories during the pre-TPS-like and TPS-like periods were similar to those reported by TPS and were based on cytologic nuclear atypia (high N:C ratio, hyperchromasia, and irregular nuclear membranes).
Re-Review and Reclassification According to TPS
All specimens in which the original cytology diagnosis was called atypical were reviewed and reassigned to TPS categories (NHGUC, AUC, SHGUC, and HGUC). 3 In accordance with TPS criteria, specimens that had benign changes, including reactive changes because of known cause of atypia (such as instrumentation, stones, polyomavirus, treatment, inflammation, and infection), were retrospectively reclassified as NHGUC. Specimens that had true tissue fragments and clusters without atypia were reclassified as NHGUC, even in voided urine. Those that had urothelial cells with an N:C ratio >0.5, if
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Cytologic-Histologic Correlation
The original and revised categories were correlated with the histologic specimens. The criteria for diagnostic correlation are listed in Table 1 . When more than 1 specimen existed for a single patient, the cytology specimen closest in date to the histology specimen was used for cytology-histology correlation.
The rate of AUC diagnoses was compared between the 2010 and 2012 (pre-TPS-like), 2013 and 2016 (TPSlike), and post-TPS reclassification. Positive predictive values (PPVs) for HGUC were calculated for each category. The false-negative rates of the benign (TPS-like reclassification) and NHGUC (post-TPS reclassification) categories and false-positive rates of the HGUC categories were compared. Statistical significance was calculated using a standard test of proportions.
Blinded Review
To simulate the application of TPS in an actual practice setting, 1 cytopathologist (R.B.), who was familiar with TPS but had not applied the system in daily practice, was provided 101 cases for a blinded review. The blinded review set included all specimens that carried an original diagnosis of atypical (for which slides were available) as well as a random selection of NHGUC, LGUC, and HGUC specimens. The cases were randomized, and the cytopathologist also was blinded to the distribution of the types of cases and the original diagnoses. The cytopathologist was provided with the TPS categorization criteria and asked to assign the cases to TPS categories.
The results of the blinded review were similarly correlated to concurrent/subsequent histologic specimens and to the pre-TPS and TPS-like systems described above.
CB Preparation
CBs were prepared on specimens (n = 36) in which the original cytologic diagnosis was inconclusive (mild cytologic atypia or large clusters suggestive of low-grade urothelial neoplasm [ LGUN] and AUC) and the cystoscopic findings revealed a lesion or mass. CBs were prepared using the agarose CB method, as previously described. 8 
Immunohistochemistry
Immunohistochemistry was performed on CB material in 3 cases. Immunohistochemical tests for prostatespecific antigen (EP1588Y rabbit monoclonal antibody, 1:100 dilution; NeoMarkers Inc, Fremont, CA) were performed on a Dako EnVision+ HRP (mouse) detection kit (Dako, Carpinteria, CA) according to the standard protocols, as indicated. Positive and negative controls were included for every assay.
RESULTS
In total, 188 atypical urine cytology cases (142 men and 46 women [3:1 ratio]; age range, 23-90 years) with subsequent histology were reviewed during the period from 2010 to 2016. Of these, 96 samples were from patients without a prior diagnosis of UC, and 92 were from patients who were undergoing surveillance because of a history of UC. Thirteen specimens were voided, 3 were catheterized, and the remaining 172 were instrumented, which included bladder washings (N = 169) and upper urinary tract washings (N = 3). The corresponding surgical specimen was obtained an average of 4 weeks after the Cancer Cytopathology September 2018 cytologic specimen and ranged from zero weeks (concurrent sample) to 33 weeks. Although it was not statistically significant, correlation between the cytologic and surgical specimen improved from 79% to 89% (P = 0.46) between the periods 2010 to 2012 and 2013 to 2016 (Table 2) . After reclassification of all specimens from 2010 through 2016 using TPS, the correlation improved further to 93%, which was statistically significant compared with the pre-TPS specimens (2010-2012; P < 0.001). Of the 64 specimens formerly called atypical that were reclassified into TPS categories, most were reclassified as NHGUC (43 specimens; 72%), followed by AUC (11 specimens; 17%) and SHGUC (6 specimens; 9%) ( Tables 3-5) . Four specimens were not reclassified, because the slides were not available for review. Of the 11 specimens that were reclassified as AUC, 3 revealed LGUC and 8 revealed HGUC on histology. Of those that were reclassified as NHGUC, 20, 19, and 3 specimens were diagnosed as NHGUC, LGUC, and HGUC, respectively, on histology; and the remaining specimen was diagnosed as atypical with features of reactive versus low-grade dysplasia.
Notably, the rate of atypical diagnoses decreased significantly from 48% to 21% (P < 0.001) and to 9% (P < 0.001) during 2010 to 2012 (pre-TPS-like), 2013 to 2016 (TPS-like), and post-TPS reclassification, respectively (Fig. 1A) . The atypical category PPV for HGUC also increased from 0.21 to 0.43 (P = 0.04) and to 0.73 (P = 0.002) during 2010 to 2012, 2013 to 2016, and after TPS reclassification, respectively ( Table 2, Fig. 1B) . The sensitivity for HGUC did not change significantly: it was 86%, 89% and 78% during 2010 to 2012, 2013 to 2016, and after TPS reclassification, respectively ( Table 2) . Specificity of the HGUC diagnosis remained high at 99% in all systems. On blinded review of 101 specimens, there still was no statistically significant change in the sensitivity of TPS for HGUC, and the PPV of an atypical diagnosis for HGUC remained significantly higher than that in the 2010 to 2012 and pre-TPS-like periods (Tables 2 and 6 ). Cancer Cytopathology September 2018
CB evaluation contributed to the final diagnosis in 24 of 36 cases (Table 7) and comprised a range of cases, including benign, atypical, HGUC, and cases with nonurothelial differentiation. The contributory CB samples provided diagnostic architectural features, such as umbrella cells overlying benign tissue fragments, fibrovascular cores for LGUN, and disorganization as well as the location of cytologic atypia within the epithelium for Cancer Cytopathology September 2018 HGUC ( Fig. 2A-C) . One specimen demonstrated frank squamous cell carcinoma (Fig. 2D ). In the remaining 12 specimens, the CB was paucicellular and thus noncontributory. The CB also provided material for immunostaining (eg, to support a diagnosis of HGUC or to confirm a nonurothelial origin of malignant cells) (Fig. 3) .
DISCUSSION
The current findings demonstrated that TPS and TPSlike methods improve the performance of urine cytology by lowering the rate of the atypical diagnosis while significantly increasing the PPV of the atypical diagnosis for HGUC. Several recent studies also have reported similar findings. [9] [10] [11] [12] [13] A single study reported an increase in atypical diagnoses (from 3% to 24% in benign cases) and a lowering of specificity; however, that study consisted primarily of voided specimens, which can have more degenerative artifacts that mimic HGUC.
14 In our pre-TPS-like period, we diagnosed AUC frequently (up to 48% of the time) and included reactive atypia because of instrumentation, stones, inflammation, and treatment in Abbreviations: AUC, atypical urothelial cells; HGUC, high-grade urothelial carcinoma;
LGUC, low-grade urothelial carcinoma; NHGUC, negative for high-grade urothelial carcinoma; SHGUC, suspicious for high-grade urothelial carcinoma. Cancer Cytopathology September 2018 the AUC category. Most of these atypical cases had an additional note describing mild cytologic atypia suggestive of LGUC. Therefore, most of these cases were reclassified as NHGUC (72%), indicating that these patients did not need definitive therapy other than routine follow-up. A major concern of TPS is the potential to miss cases of HGUC. The reported effect on sensitivity for diagnosing HGUC has also varied among studies, with some studies reporting an increase in sensitivity 15 and others reporting a decrease in sensitivity. 16 At our institution, the baseline sensitivity, at >80%, is higher than that of the pre-TPS classification in most other studies, which report 60% to 70% sensitivity for HGUC. 11, 12 In the current study, after careful reclassification of atypical cases to TPS categories, in total, 3 cases were reclassified as NHGUC but demonstrated HGUC on surgical biopsy. In the pre-TPS-like period, these cases were diagnosed as atypical, revealing large clusters of urothelial cells with overlapping of nuclei and mild cytologic atypia. These false-negative cases of HGUC may have been caused by sampling. We note that the surgical biopsy for these cases also demonstrated only focal high grade in a background of LGUC. The clinical behavior and management of lesions with focal high grade in the background of LGUC are not well established. 17 Our study was limited by its retrospective nature as well as selection bias. It included only cases in which there was a subsequent histologic specimen and also consisted predominantly of instrumented specimens; therefore, our percentages do not reflect the entire population of patients undergoing urine cytology testing. Our blinded review was similarly limited by selection bias. The 101 cases that were selected for this portion of the study were largely composed of the challenging atypical cases; however, although it is not representative of the entire population of patients in our study, we predict that this bias would only underestimate the overall sensitivity of TPS for HGUC. Our blinded review did not include knowledge about the patient's history or cystoscopic findings, which also would be expected to improve the value of using TPS. For example, the clinical history of a mass/papillary lesion on cystoscopy would prompt the pathologist to look more carefully. Furthermore, our blinded review was performed by a cytopathologist who, although familiar with TPS, had not applied the system in daily practice. A recent article that reported on the interobserver reproducibility of TPS revealed adequate precision for NGHUC but high interobserver variability (poor precision) for the other diagnostic categories. 18 Additional studies on the implementation of TPS are warranted. Finally, the current results also indicate that CBs represent a useful adjunct for diagnosis of the LGUN and NHGUC categories. The fibrovascular cores of LGUN are rarely observed in cytology preparations, but a CB can increase the ability to diagnose LGUN confidently with a cytology sample. CB samples also are useful for immunohistochemical staining, which can be an ancillary test for diagnosing HGUC as well as nonurothelial lesions, especially in laboratories that do not have immunohistochemistry protocols for non-CB cytology in place. The utility of CB has been well documented in nongynecologic exfoliative specimens 19, 20 ; however, to our knowledge, this is the first report on the utility of CB in urine cytology specimens. In the current study, CBs were only performed on residual ThinPrep material from inconclusive cytology specimens and were not performed on negative urines. The value of performing CBs on all urine samples or on a broader range of cases remains to be evaluated, and further investigation is needed. Currently, we would recommend making a CB if a papillary lesion or mass is observed on cystoscopy and the Cancer Cytopathology September 2018 cytology preparation is equivocal or if there is concern for a nonurothelial or metastatic malignancy.
CONCLUSION
TPS is useful in identifying HGUC specimens. All cases in our study that were reclassified as SHGUC or HGUC based on TPS criteria had UC on histology. TPS also distinguishes potentially neoplastic atypia from reactive atypia.
In support of TPS recommendations, our application of stringent TPS-like criteria and reclassification of cases using TPS criteria produced a significant improvement in the value of the AUC diagnosis by lowering the AUC rate and increasing the PPV of AUC for HGUC. In addition, the use of CB material can help resolve problematic cases and allow for more definitive diagnostic categorization.
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